154 related articles for article (PubMed ID: 32247568)
1. Development of a high-yield live-virus vaccine production platform using a novel fixed-bed bioreactor.
Berrie DM; Waters RC; Montoya C; Chatel A; Vela EM
Vaccine; 2020 Apr; 38(20):3639-3645. PubMed ID: 32247568
[TBL] [Abstract][Full Text] [Related]
2. Bioreactor production of rVSV-based vectors in Vero cell suspension cultures.
Kiesslich S; Kim GN; Shen CF; Kang CY; Kamen AA
Biotechnol Bioeng; 2021 Jul; 118(7):2649-2659. PubMed ID: 33837958
[TBL] [Abstract][Full Text] [Related]
3. Pseudorabies virus production using a serum-free medium in fixed-bed bioreactors with low cell inoculum density.
Nie J; Sun Y; Peng F; Han F; Yang Y; Liu X; Liu C; Li Y; Bai Z
Biotechnol Lett; 2020 Dec; 42(12):2551-2560. PubMed ID: 32816175
[TBL] [Abstract][Full Text] [Related]
4. Development of suspension adapted Vero cell culture process technology for production of viral vaccines.
Shen CF; Guilbault C; Li X; Elahi SM; Ansorge S; Kamen A; Gilbert R
Vaccine; 2019 Nov; 37(47):6996-7002. PubMed ID: 31288997
[TBL] [Abstract][Full Text] [Related]
5. Serum-free production of rVSV-ZEBOV in Vero cells: Microcarrier bioreactor versus scale-X™ hydro fixed-bed.
Kiesslich S; Vila-Chã Losa JP; Gélinas JF; Kamen AA
J Biotechnol; 2020 Feb; 310():32-39. PubMed ID: 32006630
[TBL] [Abstract][Full Text] [Related]
6. Vero cell upstream bioprocess development for the production of viral vectors and vaccines.
Kiesslich S; Kamen AA
Biotechnol Adv; 2020 Nov; 44():107608. PubMed ID: 32768520
[TBL] [Abstract][Full Text] [Related]
7. Production Process Development of Pseudorabies Virus Vaccine by Using a Novel Scale-Down Model of a Fixed-Bed Bioreactor.
Nie J; Sun Y; Peng F; Li X; Yang Y; Liu X; Li Y; Liu C; Bai Z
J Pharm Sci; 2020 Feb; 109(2):959-965. PubMed ID: 31604085
[TBL] [Abstract][Full Text] [Related]
8. Serum-free microcarrier based production of replication deficient influenza vaccine candidate virus lacking NS1 using Vero cells.
Chen A; Poh SL; Dietzsch C; Roethl E; Yan ML; Ng SK
BMC Biotechnol; 2011 Aug; 11():81. PubMed ID: 21835017
[TBL] [Abstract][Full Text] [Related]
9. Propagation of Brazilian Zika virus strains in static and suspension cultures using Vero and BHK cells.
Nikolay A; Castilho LR; Reichl U; Genzel Y
Vaccine; 2018 May; 36(22):3140-3145. PubMed ID: 28343780
[TBL] [Abstract][Full Text] [Related]
10. Production of small ruminant morbillivirus, rift valley fever virus and lumpy skin disease virus in CelCradle™ -500A bioreactors.
Rhazi H; Safini N; Mikou K; Alhyane M; Tadlaoui KO; Lin X; Venkatesan NP; Elharrak M
BMC Vet Res; 2021 Feb; 17(1):93. PubMed ID: 33639955
[TBL] [Abstract][Full Text] [Related]
11. Process intensification of EB66® cell cultivations leads to high-yield yellow fever and Zika virus production.
Nikolay A; Léon A; Schwamborn K; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2018 Oct; 102(20):8725-8737. PubMed ID: 30091043
[TBL] [Abstract][Full Text] [Related]
12. Suspension-Vero cell cultures as a platform for viral vaccine production.
Paillet C; Forno G; Kratje R; Etcheverrigaray M
Vaccine; 2009 Oct; 27(46):6464-7. PubMed ID: 19559123
[TBL] [Abstract][Full Text] [Related]
13. MDCK and Vero cells for influenza virus vaccine production: a one-to-one comparison up to lab-scale bioreactor cultivation.
Genzel Y; Dietzsch C; Rapp E; Schwarzer J; Reichl U
Appl Microbiol Biotechnol; 2010 Sep; 88(2):461-75. PubMed ID: 20617311
[TBL] [Abstract][Full Text] [Related]
14. Bioreactors for high cell density and continuous multi-stage cultivations: options for process intensification in cell culture-based viral vaccine production.
Tapia F; Vázquez-Ramírez D; Genzel Y; Reichl U
Appl Microbiol Biotechnol; 2016 Mar; 100(5):2121-32. PubMed ID: 26758296
[TBL] [Abstract][Full Text] [Related]
15. Adaptation of Vero cells to suspension growth for rabies virus production in different serum free media.
Rourou S; Ben Zakkour M; Kallel H
Vaccine; 2019 Nov; 37(47):6987-6995. PubMed ID: 31201054
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the Single-Use Fixed-Bed Bioreactors in Scalable Virus Production.
Lesch HP; Valonen P; Karhinen M
Biotechnol J; 2021 Jan; 16(1):e2000020. PubMed ID: 32971565
[TBL] [Abstract][Full Text] [Related]
17. Influenza viruses production: Evaluation of a novel avian cell line DuckCelt®-T17.
Petiot E; Proust A; Traversier A; Durous L; Dappozze F; Gras M; Guillard C; Balloul JM; Rosa-Calatrava M
Vaccine; 2018 May; 36(22):3101-3111. PubMed ID: 28571695
[TBL] [Abstract][Full Text] [Related]
18. Enhancing enterovirus A71 vaccine production yield by microcarrier profusion bioreactor culture.
Liu CC; Wu SC; Wu SR; Lin HY; Guo MS; Yung-Chih Hu A; Chow YH; Chiang JR; Shieh DB; Chong P
Vaccine; 2018 May; 36(22):3134-3139. PubMed ID: 28274636
[TBL] [Abstract][Full Text] [Related]
19. Inactivated Enterovirus 71 Vaccine Produced by 200-L Scale Serum-Free Microcarrier Bioreactor System Provides Cross-Protective Efficacy in Human SCARB2 Transgenic Mouse.
Wu CY; Lin YW; Kuo CH; Liu WH; Tai HF; Pan CH; Chen YT; Hsiao PW; Chan CH; Chang CC; Liu CC; Chow YH; Chen JR
PLoS One; 2015; 10(8):e0136420. PubMed ID: 26287531
[TBL] [Abstract][Full Text] [Related]
20. Establishment of a mink enteritis vaccine production process in stirred-tank reactor and Wave Bioreactor microcarrier culture in 1-10 L scale.
Hundt B; Best C; Schlawin N; Kassner H; Genzel Y; Reichl U
Vaccine; 2007 May; 25(20):3987-95. PubMed ID: 17391818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
